Physician profile
Allen Bowling
NPI 1790778744
$637,541.71
in general payments reported to CMS, 2019-2025
21 companies · $62.68 in 2025
The $62.68 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $205K · 2020: $58K · 2021: $89K · 2022: $144K · 2023: $92K · 2024: $50K · 2025: $62.68.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $116K · Consulting Fee: $14K · Travel and Lodging: $9,400 · Food and Beverage: $2,090.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $115,938.00 |
| Consulting Fee | $14,455.00 |
| Travel and Lodging | $9,400.12 |
| Food and Beverage | $2,090.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $300,575.62 | 2019-2024 | Mavenclad, Mavenclad, Evobrutinib |
| Genzyme Corporation | $135,666.55 | 2019-2023 | |
| Biogen, INC. | $47,905.33 | 2019-2023 | Tysabri, Vumerity |
| Genentech USA, INC. | $43,236.95 | 2019-2022 | |
| Celgene Corporation | $27,616.63 | 2019-2024 | Zeposia |
| E.R. Squibb & Sons, L.L.C. | $21,373.42 | 2020-2023 | Zeposia |
| Janssen Pharmaceuticals, INC | $19,212.52 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $13,370.33 | 2019-2023 | Kesimpta |
| Tg Therapeutics, INC. | $13,240.53 | 2022-2024 | Briumvi |
| Banner Life Sciences, LLC | $5,657.50 | 2022 | |
| Alexion Pharmaceuticals, INC. | $4,256.80 | 2019 | |
| Mallinckrodt Hospital Products INC. | $2,279.32 | 2020-2022 | |
| Janssen Global Services, LLC | $1,320.00 | 2022 | |
| Janssen Scientific Affairs, LLC | $1,320.00 | 2020 | |
| Horizon Therapeutics Plc | $285.68 | 2023 | Uplizna |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $79.12 | 2019 | |
| Abbvie INC. | $62.68 | 2025 | |
| Acorda Therapeutics, INC | $43.29 | 2021 | |
| Bioventus LLC | $32.44 | 2022 | |
| Sanofi-Aventis U.S. LLC | $7.00 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allen Bowling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.